Genetic immunotherapy for medullary thyroid carcinoma: Destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene

Thyroid

Volumn 8, Issue 12, 1998, Pages 1137-1146

  Zhang, Rusheng ^a   Baunoch, David ^a   DeGroot, Leslie J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; THYROID MEDULLARY CARCINOMA; TUMOR REGRESSION;

EID: 0032442209     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.1998.8.1137     Document Type: Article

References (34)

1. Huang H, Chen SH, Kosai K, Finegold MJ, Woo SLC 1996 Gene therapy for hepatocellular carcinoma: Long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo. Gene Therapy 3:980-987.
2. Haddada H, Ragot T, Cordier L, Duffour MT, Perricaudet M 1993 Adenoviral interleukin-2 gene transfer into P815 tumor abrogates tumorigenicity and induces antitumoral immunity in mice. Hum Gene Ther 4:703-711.
3. Li W, Diamantstein T, Blankenstein T 1990 Lack of tumorigenicity of interleukin-4 autocrine growing cells seems related to the anti-tumor function of interleukin4. Mol Immunol 27:1331-1337.
4. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E 1990 Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50:7820-7825.
5. Blankenstein T, Qin Z, Uberla K 1991 Tumor suppression after tumor cell-targeted tumor necrosis factor a transfer. J Exp Med 173:1047-1052.
6. Cordier L, Duffour M-T, Sabourin J-C, Lee MG, Cabannes J, Ragot T, Perricaudet M, Haddada H 1995 Complete recovery of mice from a pre-established tumor by direct introtumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Therapy 2:16-21.
7. Felzmann T, Ramsey WJ, Blaese RM 1997 Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1. Gene Therapy 4:1322-1329.
8. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC 1993 Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543.
9. Parkinson DR 1988 Interleukin 2 in cancer therapy. Semin Oncol 15:10-26.
10. Siegel JP, Puri RK 1991 Interleukin-2 toxicity. Clin Oncol 9:694-704.
11. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL 1995 Intratumoral injection of an adenovirus expressing interleukin-2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 92:8522-8526.
12. Connor J, Bannerji R, Saito S, Heston W, Fair W, and Gilboa E 1993 Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 177:1127-1134.
13. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E 1994 The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 152:2324-2332.
14. Coll J-L, Mesnil M, Lefebvre M-F, Lancon A, Favro MC 1997 Long term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments. Gene Ther 4:1160-1166.
15. O'Malley BW Jr, Sewell DA, Li D, Kosai K-Z, Chen S-H, Woo SLC, Duan L 1997 The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer. Mol Endocrinol 11:667-673.
16. Cordier L, Duffour MT, Sabourin JC, Lee MG, Cabannes J, Ragot T, Perricaudet M, Haddada H 1995 Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther 2:16-21.
17. Randrianarison-Jewtowkoff V, Perricaudet M 1995 Recombinant adenoviruses as vaccines. Biologicals 23:145-157.
18. Zhang R, Minemura K, DeGroot LJ 1998 Immunotherapy for medullary thyroid carcinoma by a replication-defective adenovirus transducing murine interleukin-2. Endocrinology 139:601-608.
19. Graham FL, Van Der Eb EJ 1973 A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-167.
20. Graham FL, Simley J, Russel WC, Naim R 1977 Characterization of a human cell line transformed by DNA from human adenovirus type 5. J Gene Virol 36:59-72.
21. Davis LS, Lipsky PE, Bottomly K 1994 Measurement of human and murine interleukin-2 and interleukin-4. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W (eds) Current Protocols in Immunology. Vol. 1. John Wiley & Sons, Inc, pp 6.3.1-6.3.13.
22. Bramson JL, Hitt M, Gauldie J, Graham FL 1997 Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 4:1069-1076.
23. Abbas AK, Lichtman AH, Pober JS 1994 Immunity to tumors. In: Abbas AK, Lichtman AH, Pober JS (eds) Cellular and Molecular Immunology. W.B. Saunders Company, Philadelphia, pp 357-375.
24. Strome SE, Chang AE, Shu S, Krauss JC 1996 Secretion of both IL-2 and IL-4 by tumor cells results in rejection and immunity. J Immunol 19:21-32.
25. Debruyne L 1996 Treatment of malignancy by direct gene transfer of a foreign MHC class I molecule. Cancer Immunol Immunother 43:180-189.
26. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K, Hamada H 1996 Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin-4. Cancer Res 56:1828-1833.
27. Porgador A, Tzehoral E, Vadai E, Feldman M, Eisenbach L 1993 Immunotherapy via gene therapy: Comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-γ genes. J Immunother 14:191-201.
28. Lollini P-L, DeGioranni C, Landuzzi L, Nicoletti G, Frabetti F, Cavallo F, Giovarelli M, Forni G, Modica A, Modesti A, Musiani P, Nanni P 1995 Transduction of genes coding for a histocompatibility (MHC) antigen and for its physiological inducer interferon-γ in the same cell: Efficient MHC expression and inhibition of tumor and metastasis growth. Human Gene Ther 6:743-752.
29. Jolly DJ, Willis RC, Friedmann T 1986 Variable stability of selectable provirus after retroviral transfer into human cells. Mol Cell Biol 6:1141-1147.
30. Temin HM 1989 Retrovirus vectors: Promise and reality. Science 246:983.
31. Temin HP 1986 Retrovirus vectors for gene transfer, efficient integration into, and expression of exogenous DNA in vertebrate cell genomes. In: Kucherlapati R (ed) Gene Transfer. Plenum, New York, pp 149-187.
32. Akli S, Caillaud C, Vigne E, Stratford-Perricaudet LD, Poenaru L, Perricaudet M, Kahn A, Peschanski MR 1993 Transfer of a foreign gene into brain using adenovirus vectors. Nature Gene 3:224-228.
33. Renu Prakash Y, Davidson A, Jona V, Droguett G, Horwitz MS, Chowdhurg NR, Chowdhurg JR 1997 Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. J Clin Invest 99:1098-1106.
34. O'Malley BW Jr, Cpoe KA, Chen S-H, Li D, Schwartz MR, Woo SLC 1996 Combination gene therapy for oral cancer in a murine model. Cancer Res 56:1737-1741.